Literature DB >> 7491766

HIV-1 Tat directly interacts with the interferon-induced, double-stranded RNA-dependent kinase, PKR.

N A McMillan1, R F Chun, D P Siderovski, J Galabru, W M Toone, C E Samuel, T W Mak, A G Hovanessian, K T Jeang, B R Williams.   

Abstract

We present evidence that the HIV-1 Tat protein and the RNA-dependent cellular protein kinase, PKR, interact with each other both in vitro and in vivo. Using GST fusion chromatography, we demonstrate that PKR, interacts directly with the HIV-1 Tat protein. The region in Tat sufficient for binding PKR maps within amino acids 20 to 72. In in vitro assays, the two-exon form of Tat (Tat 86) was phosphorylated by PKR, while the one exon form of Tat (Tat 72) inhibited PKR autophosphorylation and substrate phosphorylation. The ability of Tat to interact with PKR was demonstrated in both yeast and mammalian cells. Expression of PKR in yeast results in a growth suppressor phenotype which was reversed by coexpression of a one exon form of Tat. Expression of Tat 72 in HeLa cells resulted in direct interaction with PKR as detected by coimmunprecipitation with a Tat antibody. Tat and PKR also form a coimmunoprecipitable complex in cell-free extracts prepared from productively infected T lymphocytes. The interaction of Tat with PKR provides a potential mechanism by which HIV could suppress the interferon system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7491766     DOI: 10.1006/viro.1995.0014

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  57 in total

1.  Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR.

Authors:  F Demarchi; M I Gutierrez; M Giacca
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

Review 2.  Translational control of viral gene expression in eukaryotes.

Authors:  M Gale; S L Tan; M G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

3.  The 3'-untranslated regions of cytoskeletal muscle mRNAs inhibit translation by activating the double-stranded RNA-dependent protein kinase PKR.

Authors:  Jean M Nussbaum; Shobha Gunnery; Michael B Mathews
Journal:  Nucleic Acids Res       Date:  2002-03-01       Impact factor: 16.971

Review 4.  The roles of microRNAs in mammalian virus infection.

Authors:  Ralph Grassmann; Kuan-Teh Jeang
Journal:  Biochim Biophys Acta       Date:  2008-05-15

5.  Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR.

Authors:  M Benkirane; C Neuveut; R F Chun; S M Smith; C E Samuel; A Gatignol; K T Jeang
Journal:  EMBO J       Date:  1997-02-03       Impact factor: 11.598

6.  The cellular TAR RNA binding protein, TRBP, promotes HIV-1 replication primarily by inhibiting the activation of double-stranded RNA-dependent kinase PKR.

Authors:  Viraj R Sanghvi; Laura F Steel
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

7.  Sequential steps in Tat trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors.

Authors:  A Gatignol; M Duarte; L Daviet; Y N Chang; K T Jeang
Journal:  Gene Expr       Date:  1996

8.  Interaction of the interferon-induced PKR protein kinase with inhibitory proteins P58IPK and vaccinia virus K3L is mediated by unique domains: implications for kinase regulation.

Authors:  M Gale; S L Tan; M Wambach; M G Katze
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

9.  Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells.

Authors:  K V Kibler; T Shors; K B Perkins; C C Zeman; M P Banaszak; J Biesterfeldt; J O Langland; B L Jacobs
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

10.  ADAR1 interacts with PKR during human immunodeficiency virus infection of lymphocytes and contributes to viral replication.

Authors:  Guerline Clerzius; Jean-François Gélinas; Aïcha Daher; Marion Bonnet; Eliane F Meurs; Anne Gatignol
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.